Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2022-10-13
DOI
10.1080/14737167.2022.2134120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Re-emergence of Invasive Pneumococcal Disease in Germany during the Spring and Summer of 2021
- (2022) Stephanie Perniciaro et al. CLINICAL INFECTIOUS DISEASES
- Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
- (2022) Miwako Kobayashi et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Off-season RSV epidemics in Australia after easing of COVID-19 restrictions
- (2022) John-Sebastian Eden et al. Nature Communications
- Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective methodology
- (2022) Catherine Hyams et al. BMJ Open
- The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
- (2021) Frank G Sandmann et al. LANCET INFECTIOUS DISEASES
- Potential resurgence of respiratory syncytial virus in Canada
- (2021) Pascal M. Lavoie et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France
- (2021) Jacques Fourgeaud et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK
- (2021) Andrew Vyse et al. Expert Review of Vaccines
- Mortality and readmission in the year following hospitalization for pneumonia among US adults
- (2021) Ahuva Averin et al. RESPIRATORY MEDICINE
- Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021
- (2021) Sonja J. Olsen et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
- (2021) Brandon Essink et al. CLINICAL INFECTIOUS DISEASES
- The epidemiological features of pediatric viral respiratory infection during the COVID-19 pandemic in Taiwan
- (2021) Hao-Ting Hsu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Characteristics of invasive pneumococcal disease (IPD) caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in England; prospective observational cohort study, 2014-18
- (2020) Zahin Amin-Chowdhury et al. CLINICAL INFECTIOUS DISEASES
- A global agenda for older adult immunization in the COVID-19 era: A roadmap for action
- (2020) Lois A. Privor-Dumm et al. VACCINE
- Experimental Human Pneumococcal Colonisation in Older Adults is Feasible and Safe, Not Immunogenic
- (2020) Hugh Adler et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study
- (2020) Hannah Lawrence et al. PLOS MEDICINE
- Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonisation density
- (2019) E.L. German et al. VACCINE
- A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands
- (2019) Bradford D. Gessner et al. VACCINE
- Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18
- (2019) Harry Pick et al. THORAX
- Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis
- (2019) John M. McLaughlin et al. VACCINE
- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
- (2019) Almea Matanock et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program
- (2019) Charles Stoecker et al. VACCINE
- Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients
- (2018) Frank G Sandmann et al. CLINICAL INFECTIOUS DISEASES
- Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study
- (2018) Shamez N Ladhani et al. LANCET INFECTIOUS DISEASES
- Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports
- (2018) Hamid Latifi-Navid et al. Scientific Reports
- Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-Analysis of Observational Studies
- (2018) Heather L Sings et al. CLINICAL INFECTIOUS DISEASES
- Estimating the opportunity costs of bed-days
- (2017) Frank G. Sandmann et al. HEALTH ECONOMICS
- Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study
- (2017) Motoi Suzuki et al. LANCET INFECTIOUS DISEASES
- Moving beyond traditional valuation of vaccination: Needs and opportunities
- (2017) David E. Bloom et al. VACCINE
- The immunological mechanisms that control pneumococcal carriage
- (2017) Simon P. Jochems et al. PLoS Pathogens
- Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies
- (2017) Myint Tin Tin Htar et al. PLoS One
- Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea
- (2017) Jung Yeon Heo et al. PLoS One
- Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease
- (2016) G. J. HUGHES et al. EPIDEMIOLOGY AND INFECTION
- Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States
- (2016) Charles Stoecker et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?
- (2016) Mark Jit et al. Applied Health Economics and Health Policy
- Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
- (2016) Albert Jan van Hoek et al. PLoS One
- First Human Challenge Testing of a Pneumococcal Vaccine. Double-Blind Randomized Controlled Trial
- (2015) Andrea M. Collins et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort
- (2015) P. K. MYINT et al. EPIDEMIOLOGY AND INFECTION
- Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
- (2015) Chamira Rodrigo et al. EUROPEAN RESPIRATORY JOURNAL
- Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
- (2015) Marie-Josée J. Mangen et al. EUROPEAN RESPIRATORY JOURNAL
- Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
- (2015) Pauline A Waight et al. LANCET INFECTIOUS DISEASES
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
- (2015) Marc J.M. Bonten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
- (2015) Shu-ling Hoshi et al. PLoS One
- Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study
- (2014) Helmut Ostermann et al. BMC Pulmonary Medicine
- Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older Adults
- (2013) Kenneth J. Smith et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
- (2013) Lisa A. Jackson et al. VACCINE
- Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
- (2013) Bo-Hyun Cho et al. VACCINE
- Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy
- (2013) Sara Boccalini et al. Human Vaccines & Immunotherapeutics
- The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
- (2012) Albert Jan van Hoek et al. JOURNAL OF INFECTION
- Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
- (2012) Nick J. Andrews et al. VACCINE
- Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available
- (2011) Roberta Ara et al. VALUE IN HEALTH
- A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults
- (2010) Neil French et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis
- (2008) Kenneth J. Smith et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started